Financing - February 10, 2020
Chinese investment in Betagenon
Chinese investment firm Ivy Capital is investing almost three million USD into Umeå-based biotechnology firm Betagenon. Betagenon has identified an enzyme activator that is intended as a drug candidate for multiple lifestyle and age disorders such as diabetes and heart failure. Ivy Capital is now investing SEK 28.5 million into Betagenon to help support clinical […]
Clinical Trials - November 10, 2017
Positive results from Betagenon/Baltic Bio
Betagenon/Baltic Bio announces positive results from a 28 day Phase IIa trial of the first-in-class AMPK activator. The main study results are not yet finalized but review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM or above 13.3 mM at […]
Biotech Business - December 20, 2016
Betagenon receives EUR 1.8 million
The Umeå based company Betagenon receives €1,8 million, from EU’s sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and associated cardiovascular disease. “An increase in calorie intake combined with an inactive life style has brought about a global epidemic of obesity, fatty liver and […]
